Kos Pharmaceuticals to Report First Quarter Results on May 9, 2006 Conference Call at 8:30 A.M. ET
25 4월 2006 - 6:06AM
Business Wire
Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a fully integrated
specialty pharmaceutical company, will announce results for the
first quarter ended March 31, 2006, before the market opens on
Tuesday, May 9, 2006. Following the release, Kos' senior management
will host a conference call at 8:30 a.m. ET to discuss the
Company's results. The conference call will be available live via
the Internet by accessing Kos' website at www.kospharm.com. Please
go to the website at least fifteen minutes prior to the call to
register, download and install any necessary audio software. Those
who cannot access the webcast can dial into the conference call at
913-981-4911 confirmation code 4675328. A replay will also be
available on the website at www.kospharm.com or by calling
888-203-1112 domestic or international, and entering 4675328 from
2:00 PM ET on May 9, 2006 until 12:00 AM ET on May 12, 2006. If you
would like to receive notices and news regarding Kos, please visit
the Investor Relations section of the Company website and subscribe
to email alerts. Kos Pharmaceuticals, Inc. is a fully integrated
specialty pharmaceutical company engaged in developing,
commercializing, manufacturing and marketing proprietary
prescription products for the treatment of chronic diseases with a
particular focus on the cardiovascular, metabolic and respiratory
disease areas. The Company's principal product development strategy
is to reformulate existing pharmaceutical products with large
market potential to improve safety, efficacy, and patient
compliance. Kos' strategy also includes making measured investments
in new chemical entity research through in-house and sponsored
research, scientific in-licensing and general corporate development
activities. The Company currently markets Niaspan(R) and Advicor(R)
for the treatment of cholesterol disorders, Azmacort(R) for the
treatment of asthma, Cardizem(R)LA for the treatment of
hypertension and angina, and Teveten(R) and Teveten(R)HCT for the
treatment of hypertension. Kos has a strong and growing research
and development pipeline including proprietary drug delivery
technologies in solid-dose, inhalation and aerosol metered-dose
device administration to help fuel sustained, organic sales growth
into the future. Certain statements in this press release,
including statements relating to the Company's strong and growing
research and development pipeline and future sales growth are
forward-looking and are subject to risks and uncertainties which
may cause actual results to differ materially from those projected
in a forward-looking statement. These risks and uncertainties
include the Company's ability to successfully develop and
commercialize new products under development, the Company's ability
to enter into new business development and corporate opportunities,
the progress of the company's research and development pipeline,
the protection afforded by the Company's patents, the effect of
conditions in the pharmaceutical industry and the economy in
general, and the Company's ability to maintain compliance with FDA.
A more detailed discussion of risks attendant to the
forward-looking statements included in this press release are set
forth in the "Forward-Looking information: Certain Cautionary
Statements" section of the Company's Annual Report on Form 10-K for
the year ended December 31, 2005, filed with the Securities and
Exchange Commission, and in other reports filed with the SEC.
Kos (NASDAQ:KOSP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Kos (NASDAQ:KOSP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024